Roy Soumen, Samant Lalit, Ganjhu Rajeshkumar, Mukherjee Sandeepan, Chowdhary Abhay
Department of Virology, Haffkine Institute, Mumbai, India.
Radhika Ayurvedic Research and Development, Pune, Maharashtra, India.
Pharmacognosy Res. 2018 Jan-Mar;10(1):109-112. doi: 10.4103/pr.pr_121_17.
The soxhlet, cold, and ayurvedic extracts of Linn. were evaluated for antirabies activity.
Soxhlet and cold extraction method were used to extract (fruit and seed) extracts, and ayurvedic extraction of was prepared. toxicity assay was performed as per the OECD 420. LD dose was calculated by Reed and Muench method. The antirabies activity was screened in Swiss albino mice with the virus challenge dose of 10 LD (intracerebrally) in both preexposure (PE) and postexposure treatment with oral administration of extracts in Swiss albino mice and observed for 21 days. The virus load in the mice brain was evaluated by TCID50 titration method.
(ayurvedic preparation) was found to be nontoxic up to 2000 mg/kg in Swiss albino mice, i.e., 60 mg/30 g of mice, when administered (0.5 ml) orally and observed till 21 days. Up to 20% survival rate on the test group (PE of extracts) up to 14 days postinfection as compared to the virus control group (10 LD) was observed. No survival rate was observed in the postexposure group of extract; however, the survival time was increased by 4 days as compared to the virus control group. Viral load of the infected mice brain sample was estimated in vero cell line, and 3 log reduction in the virus titer was observed in text group as compared to the virus control, suggesting that extract has an antirabies activity.
To the best of our knowledge, this is the first study of antiviral activity of an ayurvedic preparation of Linn. against rabies virus. extracts have a potential antirabies activity.
In the present study, Linn. (ayurvedic preparation) extract exhibited survival (20%) in the preexposure (PE) of the virus and the survival time was increased in the postexposure treatment where the disease was established. The mortality was observed, and the viral load was determined by titration method. TCID50: tissue culture infectious dose 50; LD50: lethal dose 50; RV CVS: Rabies virus challenge virus standard; PE: Pre exposure; IC: intracerebral; PI: post infection; FITC: Fluorescein isothiocyanate.
对印楝的索氏提取物、冷提取物和阿育吠陀提取物的抗狂犬病活性进行评估。
采用索氏提取法和冷提取法提取印楝(果实和种子)提取物,并制备印楝的阿育吠陀提取物。按照经合组织420进行毒性试验。用里德和门奇法计算半数致死剂量。在瑞士白化小鼠中,用10倍半数致死剂量(脑内接种)的病毒攻击剂量对印楝提取物进行暴露前(PE)和暴露后治疗(口服给药),观察21天。通过半数组织培养感染剂量(TCID50)滴定法评估小鼠脑中的病毒载量。
在瑞士白化小鼠中,印楝阿育吠陀制剂(口服0.5毫升)给药至2000毫克/千克(即60毫克/30克小鼠),观察21天,发现无毒。与病毒对照组(10倍半数致死剂量)相比,在感染后14天内,测试组(印楝提取物暴露前组)的存活率高达20%。印楝提取物暴露后组未观察到存活率,但与病毒对照组相比,存活时间延长了4天。在 vero细胞系中估计感染小鼠脑样本的病毒载量,与病毒对照组相比,测试组的病毒滴度降低了3个对数,表明印楝提取物具有抗狂犬病活性。
据我们所知,这是首次对印楝的阿育吠陀制剂抗狂犬病病毒活性进行的研究。印楝提取物具有潜在的抗狂犬病活性。
在本研究中,印楝阿育吠陀制剂提取物在病毒暴露前(PE)表现出20%的存活率,在疾病已确立的暴露后治疗中存活时间延长。观察到死亡率,并通过滴定法测定病毒载量。TCID50:半数组织培养感染剂量;LD50:半数致死剂量;RV CVS:狂犬病病毒攻击病毒标准品;PE:暴露前;IC:脑内;PI:感染后;FITC:异硫氰酸荧光素。